Citadel Advisors’s Medifast MED Stock Holding History

Citadel Advisors’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.26M	Buy	712,800 +182,000	+34%	+$1.96M	﹤0.01%	3749
2025 Q4	$5.67M	Buy	530,800 +285,100	+116%	+$3.41M	﹤0.01%	4092
2025 Q3	$3.36M	Buy	245,700 +49,100	+25%	+$686K	﹤0.01%	5093
2025 Q2	$2.76M	Buy	196,600 +68,300	+53%	+$898K	﹤0.01%	5115
2025 Q1	$1.73M	Sell	128,300 -13,400	-9%	-$201K	﹤0.01%	5812
2024 Q4	$2.5M	Sell	141,700 -91,300	-39%	-$1.69M	﹤0.01%	5180
2024 Q3	$4.46M	Sell	233,000 -117,400	-34%	-$2.26M	﹤0.01%	4117
2024 Q2	$7.65M	Buy	350,400 +225,200	+180%	+$6M	﹤0.01%	3153
2024 Q1	$4.8M	Buy	125,200 +64,800	+107%	+$3.14M	﹤0.01%	4013
2023 Q4	$4.06M	Buy	60,400 +29,500	+95%	+$2.06M	﹤0.01%	4103
2023 Q3	$2.31M	Sell	30,900 -700	-2%	-$62.1K	﹤0.01%	4958
2023 Q2	$2.91M	Sell	31,600 -11,700	-27%	-$1.04M	﹤0.01%	4526
2023 Q1	$4.49M	Sell	43,300 -7,100	-14%	-$787K	﹤0.01%	3991
2022 Q4	$5.81M	Buy	50,400 +25,200	+100%	+$2.93M	﹤0.01%	3612
2022 Q3	$2.73M	Buy	25,200 +12,100	+92%	+$1.73M	﹤0.01%	4989
2022 Q2	$2.37M	Buy	13,100 +900	+7%	+$161K	﹤0.01%	5224
2022 Q1	$2.08M	Sell	12,200 -16,000	-57%	-$3.02M	﹤0.01%	6003
2021 Q4	$5.91M	Buy	28,200 +10,200	+57%	+$2.11M	﹤0.01%	4009
2021 Q3	$3.47M	Buy	18,000 +1,500	+9%	+$369K	﹤0.01%	5050
2021 Q2	$4.67M	Buy	16,500 +2,100	+15%	+$569K	﹤0.01%	4593
2021 Q1	$3.05M	Sell	14,400 -1,200	-8%	-$287K	﹤0.01%	5405
2020 Q4	$3.06M	Sell	15,600 -4,000	-20%	-$707K	﹤0.01%	4558
2020 Q3	$3.22M	Sell	19,600 -5,500	-22%	-$906K	﹤0.01%	3864
2020 Q2	$3.48M	Buy	25,100 +10,100	+67%	+$927K	﹤0.01%	3612
2020 Q1	$938K	Sell	15,000 -25,200	-63%	-$2.29M	﹤0.01%	5456
2019 Q4	$4.41M	Buy	40,200 +8,300	+26%	+$803K	﹤0.01%	3238
2019 Q3	$3.31M	Sell	31,900 -6,900	-18%	-$742K	﹤0.01%	3704
2019 Q2	$4.98M	Buy	38,800 +18,100	+87%	+$2.51M	﹤0.01%	3089
2019 Q1	$2.64M	Buy	20,700 +1,800	+10%	+$228K	﹤0.01%	4000
2018 Q4	$2.36M	Sell	18,900 -19,600	-51%	-$3.35M	﹤0.01%	3886
2018 Q3	$8.53M	Sell	38,500 -4,300	-10%	-$872K	﹤0.01%	2314
2018 Q2	$6.86M	Buy	42,800 +36,700	+602%	+$4.69M	﹤0.01%	2371
2018 Q1	$570K	Buy	+6,100	New	+$456K	﹤0.01%	5676
2016 Q1	–	Sell	-4,700	Closed	-$143K	–	7482
2015 Q4	$143K	Buy	4,700 +600	+15%	+$17.9K	﹤0.01%	6263
2015 Q3	$110K	Sell	4,100 -2,300	-36%	-$67K	﹤0.01%	6868
2015 Q2	$207K	Sell	6,400 -1,000	-14%	-$31.7K	﹤0.01%	6272
2015 Q1	$222K	Buy	7,400 +1,900	+35%	+$60.3K	﹤0.01%	6061
2014 Q4	$185K	Sell	5,500 -1,500	-21%	-$46.7K	﹤0.01%	6061
2014 Q3	$230K	Sell	7,000 -11,700	-63%	-$359K	﹤0.01%	5581
2014 Q2	$569K	Sell	18,700 -11,100	-37%	-$346K	﹤0.01%	4222
2014 Q1	$867K	Buy	29,800 +15,000	+101%	+$402K	﹤0.01%	3608
2013 Q4	$387K	Buy	14,800 +500	+3%	+$12.8K	﹤0.01%	4308
2013 Q3	$385K	Sell	14,300 -12,300	-46%	-$329K	﹤0.01%	4086
2013 Q2	$685K	Buy	+26,600	New	+$699K	﹤0.01%	3535

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCP

Steamboat Capital Partners Rye, New York $403M AUM 43.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Citadel Advisors's MED Position: Q2 2025 in Review

Citadel Advisors sold out of Medifast (MED) in Q2 2025, closing a stake of 56,662 shares — an estimated $745K sold.

Citadel Advisors first reported a position in MED in Q2 2013 and held it in 45 quarters. The position peaked at $23.7M in Q2 2019. 120 funds tracked by Wall St. Rank hold MED as of Q2 2025.

Citadel Advisors reported no remaining Medifast position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 56,662 Medifast shares in Q2 2025, an estimated $745K.
Citadel Advisors first reported a position in Medifast in Q2 2013 and held it in 45 quarters.
Citadel Advisors's Medifast position peaked at $23.7M in Q2 2019.
120 funds tracked by Wall St. Rank held Medifast as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.